Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 20, 2007 Billy Fisher	Many Ways to Feel Good About Wyeth The drugmaker's pipeline makes investors look forward to the next few quarters, too.
The Motley Fool July 20, 2007 Billy Fisher	Wyeth Keeps Working Its Magic The drugmaker's second-quarter boasts 12% earnings growth. Of particular promise was the reversal over first-quarter for its top seller, the antidepressant Effexor.
The Motley Fool January 23, 2009 Brian Orelli	Wyeth Isn't Cheap Enough for Pfizer The Wall Street Journal reports that Pfizer is in talks to acquire Wyeth for $60 billion or more. Should they do it?
The Motley Fool March 23, 2005 Jeff Hwang	Wyeth Ups the Ante The drugmaker raises first-quarter guidance, primarily on strong sales of Prevnar and Enbrel.
The Motley Fool July 24, 2009 Brian Orelli	Pfizer's Bride Puts on the Makeup Pfizer may not be getting a powerhouse revenue driver in Wyeth, but at least its bride knows how to make the bottom line look pretty.
The Motley Fool July 20, 2006 Stephen D. Simpson	Wyeth Wins Again Another respectable quarter and a decent pipeline make this pharmaceutical stock worth watching.
The Motley Fool April 29, 2009 Brian Orelli	The Other 33.1% of Pfizer Reports The take-home message for current and future Pfizer shareholders from Wyeth's quarterly report is that they're not getting a growth monster, but Wyeth's revenue is fairly stable.
The Motley Fool July 20, 2005 Stephen D. Simpson	Why Not Wyeth? Wyeth has turned itself around, but is it still an attractive big-pharma investment?
The Motley Fool May 4, 2011 Brian Orelli	For Pfizer, Breaking Up Is Hard to Do CEO Ian Read pushes back the decision on the company's breakup until 2012.
The Motley Fool April 23, 2008 Brian Orelli	Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs.
The Motley Fool January 30, 2007 Brian Lawler	Wyeth's Slow Growth Wyeth releases its 2006 financial results and guides for another year of slow growth. Investors, take note.
The Motley Fool April 20, 2005 Stephen D. Simpson	Wyeth Looking Healthier Improving sales are helping this troubled drugmaker recover a little faster. Big pharma investors might see Wyeth as one of the more interesting growth and turnaround candidates in the industry.
The Motley Fool October 15, 2009 Brian Orelli	An Ode to Wyeth Pfizer weds Wyeth today and the WYE ticker will be gone forever.
The Motley Fool January 22, 2004 Alyce Lomax	Worries for Wyeth Despite pain-free vaccine, the drug maker's results are still painful.
BusinessWeek November 14, 2005 Gene G. Marcial	Rivals Are Eyeing Wyeth Drugmaker Wyeth is the most attractive in the beleaguered pharma sector.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool February 25, 2010 Brian Orelli	13 Is Pfizer's Lucky Number Inherited from Wyeth, Prevnar 13 could be a goldmine for Pfizer.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer Dodges a Bullet The drugmaker slips through an advisory committee unscathed.
The Motley Fool June 15, 2010 Brian Orelli	Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer.
The Motley Fool June 13, 2008 Brian Orelli	Some Insight Into Incyte's Data Incyte's rheumatoid arthritis drug looks promising, according to early numbers.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool October 21, 2005 Stephen D. Simpson	Is Wyeth Your Happy Pill? The pharma has crawled back from scandal, but growth prospects aren't looking so healthy. Investors should not be in a hurry to pay a premium for these shares today.
The Motley Fool July 25, 2008 Brian Orelli	Generic Heartburn at Wyeth Revenue from its heartburn drug Protonix dropped 59% year over year after Teva Pharmaceuticals and Sun Pharmaceuticals launched their generic versions of the drug.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
The Motley Fool August 3, 2007 Billy Fisher	Stormy Waters at Wyeth The downward trend in the price of Wyeth shares may have painted a grim picture for the stock's future; however, the company has already demonstrated its ability to grow revenues despite the competition from generics.
The Motley Fool April 21, 2006 Stephen D. Simpson	Wily Wyeth For the most part, this business will produce high-single-digit revenue growth, and hopefully low-teens growth in earnings and cash flow. That means investors should be a little conservative buying in, but patient when holding.
The Motley Fool October 25, 2011 Brian Orelli	Anemic Growth in All the Right Places Amgen's anemia drugs decline, but that's not its future anyway.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Red and White Results at Amgen At current levels, this biotech titan could be worth a further look from investors.
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
The Motley Fool August 28, 2008 Brian Orelli	Schering and Pfizer Aren't Horsing Around Schering sells some animal health products to Pfizer to keep the EU happy.
The Motley Fool January 31, 2006 Stephen D. Simpson	Wyeth: Waiting on the Pipeline While Wyeth's growth today is modest, the late-stage pipeline could pay off. Investors, take note.
The Motley Fool September 19, 2007 Billy Fisher	Prevnar Problems at Wyeth? New strains of bacteria might make the popular pneumonia vaccine less effective. While Prevnar might come under siege from superbugs, one doubts that Wyeth's stock price will become similarly cure-resistant.
The Motley Fool October 19, 2006 Brian Lawler	A Yawn and More Growth From Wyeth Investors, the numbers aren't all that new, but they are good. With its guidance of $3.12 to $3.18 in EPS for the year and a steadily increasing dividend, Wyeth is a good candidate for investors who want to get a start in this sector
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool January 12, 2012 Brian Orelli	What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see.
Fast Company February 2009 Elizabeth Svoboda	Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits.
The Motley Fool August 28, 2008 Brian Orelli	Me-Too Drugs: Are They Worth It? These drugs have less risk, but also usually bring less of a reward to the companies that make them.
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
The Motley Fool August 3, 2011 Brian Orelli	Ignore Pfizer's Financials for Now It's the pipeline that matters.
The Motley Fool March 7, 2008 Brian Orelli	A Heavy Price for Wyeth and Pfizer They're ordered to pay millions because their hormone therapies may carry a higher risk of breast cancer.
The Motley Fool October 6, 2006 Brian Lawler	Wyeth Makes Investors Happy It's facing some challenges, but there's a lot for investors to like about this drug company.
The Motley Fool September 19, 2008 Brian Orelli	Skinning the Competition J&J's psoriasis drug candidate beats Amgen and Wyeth's Enbrel.
The Motley Fool September 24, 2009 Brian Orelli	Wyeth's Biting the Hand That Feeds It Wyeth decides to sue the Food and Drug Administration after it approved Orchid Chemicals & Pharmaceuticals' generic version of its antibiotic Zosyn.
The Motley Fool March 28, 2008 Brian Orelli	Wyeth Fires to Get Back on Fire The first round of Wyeth's cuts look like the right move for the big pharma company.
The Motley Fool March 7, 2011 Brian Orelli	Kids, Vaccines, and Deaths a Bad Combination Pfizer and Sanofi may not to be to blame, but when investing in drugmakers, you always have to be worried about drug safety. Fortunately this doesn't look like one of those issues.
The Motley Fool September 3, 2009 Brian Orelli	Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing.
Chemistry World February 4, 2009 Matt Wilkinson	GSK targets autoimmune biologics GSK recently signed seven drug development deals that could see the company release a suite of drugs to treat inflammatory diseases ranging from rheumatoid arthritis to lupus.
The Motley Fool September 22, 2009 Brian Orelli	Pfizer and Wyeth Put the Horse Before the Cart The pharmas' animal-business divestiture brings them one step closer to unity.